Aim: Cellular or exosomal expression of an oncofetal lncRNA gene H19, was evaluated during androgen stimulation via dihydrotestosterone (DHT) or androgen receptor (AR) blockage via enzalutamide in cultured hormone-sensitive prostate cancer (PCa) cells which overexpress the androgen receptor (LNCaP-AR+) in the present study.
Material and Methods: Cells were treated using DHT (10 nM) and/or enzalutamide (10 uM) for 24 hours. Cellular, and exosomal expression of H19 was investigated using a quantitative polymerase chain reaction assay.
Results: Our findings revealed that the mean cellular H19 expression decreased approximately 2.3 fold after androgen stimulation of PCa cells. Enzalutamide restored DHT effect with AR blockage, and we found increased H19 expression with the combined use of DHT, and enzalutamide compared with the levels in the control cells (p
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
